作者: A G Solimando , A Brandl , K Mattenheimer , C Graf , M Ritz
DOI: 10.1038/LEU.2017.287
关键词:
摘要: Cell adhesion in the multiple myeloma (MM) microenvironment has been recognized as a major mechanism of MM cell survival and development drug resistance. Here we addressed hypothesis that protein junctional molecule-A (JAM-A) may represent novel target clinical biomarker MM. We evaluated JAM-A expression lines 147 patient bone marrow aspirates biopsies at different disease stages. Elevated levels patient-derived plasma cells were correlated with poor prognosis. Moreover, circulating soluble (sJAM-A) significantly increased patients compared controls. Notably, vitro inhibition impaired migration, colony formation, chemotaxis, proliferation viability. In vivo treatment an anti-JAM-A monoclonal antibody (αJAM-A moAb) tumor progression murine xenograft model. These results demonstrate therapeutic targeting potential to prevent progression, lead us propose MM, sJAM-A serum-based marker for stratification.